| scholarly article | Q13442814 |
| P2093 | author name string | Lynn Zechiedrich | |
| David Steffen | |||
| Richard J Hamill | |||
| James Versalovic | |||
| Richard Sucgang | |||
| Lauren Becnel Boyd | |||
| Sonia K Morgan-Linnell | |||
| Javier Rojo Jimenez | |||
| Lori Banks Horton | |||
| Merry J Maynard | |||
| P2860 | cites work | Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus | Q28343420 |
| Fluoroquinolone action against mycobacteria: effects of C-8 substituents on growth, survival, and resistance | Q28369156 | ||
| Increased fluoroquinolone resistance with time in Escherichia coli from >17,000 patients at a large county hospital as a function of culture site, age, sex, and location | Q33314977 | ||
| DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance | Q33740527 | ||
| Enhanced in vivo fitness of fluoroquinolone-resistant Campylobacter jejuni in the absence of antibiotic selection pressure | Q33756688 | ||
| Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies | Q34347864 | ||
| Plasmid-mediated quinolone resistance in clinical isolates of Escherichia coli from Shanghai, China | Q35102456 | ||
| Contribution of the C-8 substituent of DU-6859a, a new potent fluoroquinolone, to its activity against DNA gyrase mutants of Pseudomonas aeruginosa | Q35115957 | ||
| Ciprofloxacin-induced, low-level resistance to structurally unrelated antibiotics in Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus | Q35816058 | ||
| Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli | Q35879095 | ||
| Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections. | Q36048167 | ||
| New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate | Q36094929 | ||
| Contributions of the combined effects of topoisomerase mutations toward fluoroquinolone resistance in Escherichia coli | Q36295431 | ||
| Use of a broad-host-range gyrA plasmid for genetic characterization of fluoroquinolone-resistant gram-negative bacteria | Q36755663 | ||
| Quinolone-mediated bacterial death. | Q36921143 | ||
| Enhancement of fluoroquinolone activity by C-8 halogen and methoxy moieties: action against a gyrase resistance mutant of Mycobacterium smegmatis and a gyrase-topoisomerase IV double mutant of Staphylococcus aureus | Q39478440 | ||
| Topoisomerase Poisons: Harnessing the Dark Side of Enzyme Mechanism | Q40476934 | ||
| Bacterial resistance to fluoroquinolones: lessons to be learned | Q40633563 | ||
| Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates | Q42234726 | ||
| Comparative in vitro and in vivo activity of the C-8 methoxy quinolone moxifloxacin and the C-8 chlorine quinolone BAY y 3118. | Q43542840 | ||
| In vitro antimicrobial activity of gatifloxacin compared with other quinolones against clinical isolates from cancer patients | Q45137202 | ||
| Effect of subinhibitory concentrations of ciprofloxacin on Mycobacterium fortuitum mutation rates | Q46546957 | ||
| Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase | Q46862305 | ||
| The barrier to recombination between Escherichia coli and Salmonella typhimurium is disrupted in mismatch-repair mutants | Q50192890 | ||
| Relative contributions of the AcrAB, MdfA and NorE efflux pumps to quinolone resistance in Escherichia coli. | Q53939108 | ||
| A conspicuous adaptability to antibiotics in the Escherichia coli mutator strain, dnaQ49. | Q54085756 | ||
| Dose-related selection of fluoroquinolone-resistant Escherichia coli. | Q54437857 | ||
| Highly Variable Mutation Rates in Commensal and Pathogenic Escherichia coli | Q56944671 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Escherichia coli | Q25419 |
| levofloxacin | Q424193 | ||
| P304 | page(s) | 229-234 | |
| P577 | publication date | 2008-10-06 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Relationships among ciprofloxacin, gatifloxacin, levofloxacin, and norfloxacin MICs for fluoroquinolone-resistant Escherichia coli clinical isolates | |
| P478 | volume | 53 |
| Q100533695 | Antibiotic resistance and virulence of Escherichia coli strains isolated from animal rendering plant |
| Q37894832 | Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria |
| Q36080959 | De Novo Characterization of Genes That Contribute to High-Level Ciprofloxacin Resistance in Escherichia coli |
| Q53687829 | Discovery and Optimization of Indolyl-Containing 4-Hydroxy-2-Pyridone Type II DNA Topoisomerase Inhibitors Active against Multidrug Resistant Gram-negative Bacteria. |
| Q36156268 | DprB facilitates inter- and intragenomic recombination in Helicobacter pylori |
| Q38682369 | Escherichia coli DNA ligase B may mitigate damage from oxidative stress. |
| Q62635883 | Evaluation of quinolones for use in detection of determinants of acquired quinolone resistance, including the new transmissible resistance mechanisms qnrA, qnrB, qnrS, and aac(6')Ib-cr, in Escherichia coli and Salmonella enterica and determinations o |
| Q42111161 | Expression of multidrug efflux pump genes acrAB-tolC, mdfA, and norE in Escherichia coli clinical isolates as a function of fluoroquinolone and multidrug resistance |
| Q39772178 | Farm level risk factors for fluoroquinolone resistance in E. coli and thermophilic Campylobacter spp. on poultry farms. |
| Q40623215 | High prevalence of plasmid-mediated quinolone resistance determinants in Enterobacter cloacae isolated from hospitals of the Qazvin, Alborz, and Tehran provinces, Iran. |
| Q44295854 | In Vitro Synergy of Biochanin A and Ciprofloxacin against Clinical Isolates of Staphylococcus aureus. |
| Q35085177 | Incidence rate of fluoroquinolone-resistant gram-negative rod bacteremia among allogeneic hematopoietic cell transplantation patients during an era of levofloxacin prophylaxis. |
| Q93046921 | Levofloxacin: Insights Into Antibiotic Resistance and Product Quality |
| Q46789377 | Magainin 2 induces bacterial cell death showing apoptotic properties |
| Q42234726 | Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates |
| Q49924023 | Molecular epidemiology of fluoroquinolone resistant Salmonella in Africa: A systematic review and meta-analysis |
| Q35131669 | Multidrug efflux pumps from Enterobacteriaceae, Vibrio cholerae and Staphylococcus aureus bacterial food pathogens |
| Q28534076 | Novel Conserved Genotypes Correspond to Antibiotic Resistance Phenotypes of E. coli Clinical Isolates |
| Q64249566 | Optimized Preparation of Levofloxacin Loaded Polymeric Nanoparticles |
| Q37595559 | Quinolones: action and resistance updated |
| Q40481349 | Rapid Detection of Genomic Mutations in gyrA and parC Genes of Escherichia coli by Multiplex Allele Specific Polymerase Chain Reaction. |
| Q34538298 | Specific patterns of gyrA mutations determine the resistance difference to ciprofloxacin and levofloxacin in Klebsiella pneumoniae and Escherichia coli |
| Q24625342 | Sublethal antibiotic treatment leads to multidrug resistance via radical-induced mutagenesis |
| Q61796926 | Sugar and iron: Toward understanding the antibacterial effect of ciclopirox in Escherichia coli |
| Q54332036 | Synthesis and antimicrobial activities of oximes derived from O-benzylhydroxylamine as FabH inhibitors. |
| Q28534775 | Toward repurposing ciclopirox as an antibiotic against drug-resistant Acinetobacter baumannii, Escherichia coli, and Klebsiella pneumoniae |
| Q55215658 | Wicked: The untold story of ciprofloxacin. |
Search more.